pharmaceutical investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
pharmaceutical investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Prismo Metals Reports 4,811 g/t Silver and Confirms Deep Porphyry Copper Potential Beneath Historic Silver King Mine, near Resolution Copper in Arizona
Steadright Removes Titanbeach One Technical Report And Retains Qualified Geologist For New Technical Report
